CLDX Winning Stock Forecast

Source: pixnio

Celldex Therapeutics, Inc., incorporated on December 9, 1983, is a bio-pharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. The Company is using the technologies to develop targeted immunotherapeutics consisting of protein-based molecules, such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases. The Company’s lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII). Its Glembatumumab vedotin (also referred to as CDX-011) is a targeted antibody-drug conjugate for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody that is designed to enhance a patient’s immune response against their cancer. The Company’s earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. The Company’s pipeline also includes CDX-0158 and CDX-3379.

Source: flickr

Celldex’s pipeline is comprised of immunotherapies and other targeted biologics. Their drug candidates are derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases. They are aimed at addressing market opportunities for which they believe current therapies are inadequate or non-existent.

Over the period from 3rd January to 3rd February CLDX saw a stock rise of 130.93% this was the highest performing stock over that period from the BioTech stocks I Know First package.

Over the course of the 2018, the stock reached a high of $2.86 and a low of $0.18, which as a result has the increased attention of keen investors who are following the progress of the asset as it gets closer to a significant historic high price or low value. The stock currently stands at $0.59.

Current I Know First subscribers received a bullish CLDX forecast on 3^rd January. With a signal of 1.82 for the month-long time frame.

The graph below shows this remarkable return for CLDX stock over this time period in-line with the I Know First forecast:

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.

How to interpret this diagram

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.